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Abstract
Background: Mainland China experienced pandemic influenza H1N1 (2009) virus (pH1N1) with peak activity during
November-December 2009. To understand the geographic extent, risk factors, and attack rate of pH1N1 infection in China
we conducted a nationwide serological survey to determine the prevalence of antibodies to pH1N1.
Methodology/Principal Findings: Stored serum samples (n=2,379) collected during 2006-2008 were used to estimate
baseline serum reactogenicity to pH1N1. In January 2010, we used a multistage-stratified random sampling method to
select 50,111 subjects who met eligibility criteria and collected serum samples and administered a standardized
questionnaire. Antibody response to pH1N1 was measured using haemagglutination inhibition (HI) assay and the weighted
seroprevalence was calculated using the Taylor series linearization method. Multivariable logistic regression analyses were
used to examine risk factors for pH1N1 seropositivity. Baseline seroprevalence of pH1N1 antibody (HI titer $40) was 1.2%.
The weighted seroprevalence of pH1N1 among the Chinese population was 21.5%(vaccinated: 62.0%; unvaccinated: 17.1%).
Among unvaccinated participants, those aged 6-15 years (32.9%) and 16-24 years (30.3%) had higher seroprevalence
compared with participants aged 25–59 years (10.7%) and $60 years (9.9%, P,0.0001). Children in kindergarten and
students had higher odds of seropositivity than children in family care (OR: 1.36 and 2.05, respectively). We estimated that
207.7 million individuals (15.9%) experienced pH1N1 infection in China.
Conclusions/Significance: The Chinese population had low pre-existing immunity to pH1N1 and experienced a relatively
high attack rate in 2009 of this virus. We recommend routine control measures such as vaccination to reduce transmission
and spread of seasonal and pandemic influenza viruses.
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Introduction
On June 11, 2009, the World Health Organization (WHO)
declared the first influenza pandemic of the21st century caused by
a novel swine-origin influenza A H1N1 virus [1], which contains
gene segments derived from classical swine H1N1 virus, human
seasonal influenza H3N2 virus, avian influenza H1N1 virus and
Eurasian swine H1N1 influenza virus [2].
Studies on the extent of infection with pH1N1 are essential for
pandemic severity assessment and for the development of response and
vaccination strategies. Modeling methods have been used to estimate
the incidence of infection during the pandemic period, using clinical
surveillance data in which only patients with influenza-like illness who
seek care are captured, while those who do not seek care or have
asymptomatic infections are excluded [3–5]. These estimates provide
useful and timely information, but may lead to an underestimation of
the actual number of infections. Therefore, serological studies have
been recommended to more accurately estimate the attack rate and the
extent of infection of 2009 pandemic influenza A H1N1 (pH1N1) virus
infection [6]. Such serological studies have previously been conducted
using convenience serum samples [7–13]. Miller, et al. estimated that
approximately one in every three children in the United Kingdom
(UK) had serological evidence of pH1N1 infection which was nearly
ten times higher than the estimated incidence of pH1N1 from clinical
surveillance [7]. Chen, et al. estimated that 13% of participants from a
community cohort of adults in Singapore had serological evidence of
pH1N1 infection following the June to September 2009 wave of
pH1N1 [8].
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detected in mainland China. Activity for pH1N1 remained low
until the end of August, increased sharply in September, and
peaked in late November. The purpose of this study was to
estimate the baseline cross reactive antibody response to pH1N1
virus prior to introduction of the virus in mainland China using a
convenience sample of serum collected during 2006–2008, to
estimate the attack rate or seroprevalence of pH1N1 infection after
the first wave of pH1N1 infection in January 2010 using a
serological study (Figure S1), and to examine factors associated
with serological response to pH1N1 infection. We conducted a
multi-stage random-sampling serological study to determine the
seroprevalence of pH1N1 in mainland China representative of
different areas and ages, to understand the geographic extent of
infection and to assess risk factors of pH1N1 infection in China.
Combining the findings from these two studies, we were able to
also estimate the attack rate of pH1N1 infection after the first wave
of the pandemic in mainland China.
Results
Baseline cross reactive antibody response to pandemic
influenza H1N1 (2009) virus
The baseline cross reactive antibody response to pH1N1
infection (HI titer of $40) by age group among the convenience
sample of 2,379 individuals is shown in Table 1. The overall
baseline cross reactive antibody response to pH1N1 infection
among the population was 1.2% (95% confidence interval [95%
CI]: 0.7–1.6%). Examining the data by age group showed that
individuals aged 16–24 had the highest baseline cross reactive
antibody response to pH1N1 infection (3.3%) in comparison with
individuals in other age categories (0–5 years: 0%, 6–15 years:
1.1%, 25–59 years: 0.6%, $60 years: 2.0%).
Characteristics of study population of the cross-sectional
seroprevalence study
In January 2010 we enrolled 50,458 subjects in the cross-
sectional study. Of those, 50,403 blood samples were collected and
50,350 participants completed both the questionnaire and blood
sample collection. Of these, 239 subjects were excluded because of
missing demographic data (n=161) or having insufficient serum
sample (n=78), leaving data from 50,111 (99.5%) subjects for
analysis, Demographic characteristics of the entire sample are
shown in Table 2. There were no statistically significant
differences in the distribution of the data by age group, gender,
region, and community setting (capital city, urban area, or rural)
between the study subjects and the true Chinese population. There
were 7,799 (15.6%) subjects who reported receiving the pH1N1
vaccine compared with 42,300 (84.4%) who reported not receiving
the pH1N1 vaccine, and 12 (0.02%) subjects reported unknown
vaccination history. Using sampling weight constructed based on
the multi-stage random sampling design to adjust for oversampling
of certain age groups and community settings, the weighted
proportion of the Chinese population estimated to have received
pH1N1 vaccine was 9.7%. Among unvaccinated participants,
39.4% were children in kindergarten or students, 7.3% were
children in family care, 4.6% were teachers, doctors or nurses
while nearly half (48.7%) reported other occupation (Table 2).
Weighted prevalence of pandemic influenza H1N1 (2009)
virus
Among 50,111 study subjects, 14,776 (29.5%) were antibody
positive for the pH1N1 virus. Since we employed a multi-stage
sampling method we adjusted for age and other factors to calculate
a weighted pH1N1 seroprevalence of 21.5% (95% CI: 20.5–22.5)
in the whole Chinese population. The weighted prevalence of
pH1N1 antibody response for the subjects who reported receiving
vaccine was significantly higher 62.0% (95% CI: 58.8–65.3) than
subjects who did not report receiving the vaccine 17.1% (95% CI:
16.1–18.0) (p,0.0001).
Among the unvaccinated study population, we found that
individuals aged 6–15 years (32.9%) and 16–24 years (30.3%) had
the highest weighted prevalence, individuals aged 25–59 years
(10.7%) and $60 years (9.9%) had the lowest (Table 3). When
examining the weighted seroprevalence among the unvaccinated
study population, we found that students had the highest weighted
seroprevalence (34.9%), followed by children in kindergarten
(26.2%), and participants with other occupations (11.1%). Further,
among unvaccinated subjects, weighted prevalence of pH1N1 in
eastern provinces (15.2%) was statistically significantly lower than
the prevalence in both central (18.6%) and western provinces
(19.3%). Among the unvaccinated, the weighted prevalence of
pH1N1 infection in other urban areas (19.6%) was statistically
significantly higher than the weighted prevalence in rural areas
(15.8%), and higher than that in capital cities (17.1%) though the
difference between capital cities and other urban areas was not.
To control for possible interactions between factors, multivar-
iable logistic regression was used to estimate the odds ratio (OR)
and 95% Confidence Interval (95% CI) for factors associated with
pH1N1 antibody response among subjects who reported not
receiving the pH1N1 vaccine (Table 4). The adjusted odds of
seropositivity to pH1N1 infection for the eastern region (OR: 0.80,
95% CI: 0.68–0.93) were statistically significantly lower than the
odds of infection in the western region. There was no statistically
significant difference in the odds of infection between the central
region (OR: 1.02, 95% CI: 0.89–1.18) and the western region.
The odds of pH1N1 infection in the rural areas was statistically
significantly lower (OR: 0.79, 95% CI: 0.69–0.90) compared with
the odds of infection in other urban areas. The odds of pH1N1
infection in capital city areas (OR: 0. 97, 95% CI: 0.83–1.12) were
Table 1. Proportion of baseline sera reactive to pandemic influenza H1N1 (2009) virus in each age group, 2006–2008.
Age (years) No. of Samples tested(n=2379) No. of positive samples Proportion of positive antibody % 95%CI
0–5 436 0 0 0–0.7
6–15 556 6 1.1 0.4–2.3
16–24 360 12 3.3 1.7-5.8
25–59 534 3 0.6 0.1–1.6
60– 493 10 2.0 1.0–3.7
doi:10.1371/journal.pone.0017919.t001
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significantly different from those in other urban areas. Children
in kindergarten (OR: 1.36, 95% CI: 1.05–1.76) and students (OR:
2. 04, 95% CI: 1.64–2.54) had significantly higher odds of pH1N1
seropositivity than children who were in family care. In contrast,
subjects with other occupation (OR: 0.46, 95% CI: 0.37–0.58) had
lower odds of pH1N1 antibody response compared with children
in family care. The odds of seropositivity were not statistically
different by gender (Table 4).
Attack rate of pandemic influenza H1N1 (2009) virus in
the Chinese Population
We estimated the attack rate of infection of pH1N1 from May
2009 to January 2010 to be 15.9% (95% CI: 15.3–16.5%) by
subtracting the baseline cross reactive antibody response to
pH1N1 infection (1.2%) from the estimated seroprevalence of
pH1N1 infection from our study (17.1%). The attack rates by age
group were 24.7% (0–5 y), 31.8% (6–15 y), 27% (16–24 y), 10.1%
(25–59 y) and 8% (60+y). The estimated number of pH1N1
infections was calculated by multiplying the estimated seroinci-
dence of infection (15.9%) by the total population on mainland
China (1,306.3 million) to give a total number of pH1N1 cases of
207.7 million.
Discussion
We aimed to estimate the adjusted seroprevalence of antibodies
to pH1N1 among Chinese adults and children, to estimate the
total number of persons infected in China, and to understand risk
factors for infection among this population. We found that the
seropositivity to pH1N1 was 17.1% after excluding individuals
who reported receiving the pH1N1 vaccine, but that the baseline
pre-pandemic seropositivity percent was 1.2%, giving an attack
rate of pH1N1 in the first pandemic wave of 15.9% in the period
May 2009 to January 2010. Further, our study showed that the
seroprevalence of pH1N1 infection was higher in the central and
western regions compared with the eastern region, higher in urban
Table 2. Characteristics of study population in the cross-sectional survey, January 2010.
Demographic
Characteristics
Study subjects N(%)
(n=50,111)
Unvaccinated subjectsN(%)
(n=42,300)
True Chinese population per
millionN(%) (n=1,306.3 million)
Age group, years
0–5 9,914 (19.8%) 9,512 (22.5) 84.9 (6.5)
6–15 10,500 (21.0%) 7,409 (17.5) 197.3 (15.1)
16–24 9,513 (19.0%) 7,485 (17.7) 164.6 (12.6)
25–59 10,684 (21.3%) 8,984 (21.2) 689.7 (52.8)
$60 9,500 (18.9%) 8,910 (21.1) 169.8 (13.0)
Gender
Male 24,090 (48.1%) 20,430 (48.3) 659.7 (50.5)
Female 26,021 (51.9%) 21,870 (51.7) 646.6 (49.5)
Occupation
#
Children in family care
1 3,150 (6.3%) 3088 (7.3)
Children in kindergarten 7,118 (14.2%) 6763 (16.0)
Student 14,014 (28.0%) 9871 (23.4)
Teacher 936 (1.9%) 609 (1.4)
Doctor or nurse 2,632 (5.3) 1311 (3.2)
Other 22,174 (44.3%) 20579 (48.7)
Urban/rural
Capital city (Municipalities) 16,558 (33.0%) 13321 (31.5) 115 (8.8)
Other urban areas 16,496 (32.9%) 13,791 (32.6) 446.8 (34.2)
Rural areas 17,057 (34.0%) 15,188 (35.9) 744.6 (57.0)
Region
Eastern 18,314 (36.6%) 15,483 (36.6) 437.6 (33.5)
Central 18,067 (36.0%) 15,276 (36.1) 502.9 (38.5)
Western 13,730 (27.4%) 11,541 (27.3) 365.8 (28.0)
Vaccination of pH1N1
*
Yes 7,799 (15.6%)
No 42,300 (84.4%)
Developed a ‘‘cold’’ since May 1,2009
Yes 23,867 (47.6%) 19,971 (47.2%)
No 26,244 (52.4%) 22329 (52.8)
NOTE. # 87 participants were missing occupation data, and 79 unvaccinated participants were missing occupation data.
1Children in family care is defined as the persons aged #15 years that are not student or Children in Kindergarten, or did not worked in any organizations or units.
*12 participants reported unknown vaccination history of pH1N1.
doi:10.1371/journal.pone.0017919.t002
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To our knowledge, this is the first time a multi-stage random-
sampling serological study to investigate the seroprevalence of
pH1N1 in China has been conducted. We used a serological
survey to examine the seroprevalence of pH1N1 because of
limitations of the clinical surveillance system in capturing true
prevalence of pH1N1 infection. The clinical surveillance system-
atically captures individuals who seek medical care at hospitals
that conduct the surveillance. However, it has been reported that
many 2009 pandemic influenza H1N1 cases were mild [14–16]
and many of those with infection may not have sought medical
care and would not have been tested for infection. Additionally,
studies have suggested that asymptomatic pH1N1 infection may
be common [14]. Our serosurvey results suggest that approxi-
mately 207.7 million people in mainland China were infected with
pH1N1 from May 2009 to January 2010. As of 31 January 2010,
126,449 clinical pH1N1 cases confirmed through respiratory
specimens were reported in mainland China [17], implying that
each such confirmed case of pH1N1 represented a possible 1,630
infections.
Our study had several limitations. The haemagglutination-
inhibition (HI) assay may not be the most sensitive assay to detect
low levels of pH1N1 compared to for example microneutraliza-
tion, and we may have underestimated seropositivity both in the
baseline and the serological survey samples. Also though we
recorded a high percentage of seropositive persons who did not
report symptoms, this may be due to potential recall bias and we
were unable to confirm the presence or absence of respiratory
symptoms. Lastly, we were not able to confirm receipt or not of
pH1N1 vaccine, and it is possible that people reported receipt of
different vaccines as pH1N1 vaccine.
Our study showed school-aged population and young adults
had the highest attack rates of pH1N1, which is consistent with
studies from the UK and Hong Kong [7,13]. The attack rate of
pH1N1(31.8%) among individuals aged 6–15 yrs was lower
compared with individuals aged 5–14 yrs (42%) in the UK study
and the attack rate among individuals in Hong Kong aged 5–14
years was 43.4%) [7,13].
Our findings also indicated that 1.2% of the population had
baseline cross reactive antibody response to pH1N1 and only 2.0%
of adults aged $60 years had an antibody response. Unlike other
countries such as the United States, the United Kingdom,
Germany, and Finland [7,9,18,19], older adults in China had a
lower baseline antibody response to the pH1N1 virus. These
findings were similar to findings from a serological study
conducted in the Guangxi province of China and other studies
in Japan and Singapore [8,20–23]. The lower antibody response
Table 3. Weighted seroprevalence of 2009 pandemic H1N1 virus antibodies by demographic characteristics among subjects who
reported not receiving pH1N1 vaccine (N=42,300).
Demographic Characteristics Samples tested
Positive
samples
pH1N1
antibody (%)
Weighted
prevalence of
pH1N1 antibody (%)
95% Confidence
Interval
Age group, years
0–5 9512 2550 26.8 24.7 22.4–26.9
6–15 7409 2677 36.1 32.9 30.2–35.6
16–24 7485 2369 31.6 30.3 27.7–32.9
25–59 8984 1255 14.0 10.7 9.5–12.0
$60 8910 768 8.6 9.9 8.2–11.7
Gender
Male 20430 4893 24.0 18.2 16.7–19.6
Female 21870 4726 21.6 16.0 14.8–17.2
Occupation
#
Children in family care 3088 662 21.4 20.8 17.6–24.1
Children in kindergarten 6763 1967 29.1 26.2 23.0–29.5
Student 9871 3785 38.3 34.9 32.5–37.3
Teacher 609 136 22.3 16.1 7.9–24.4
Doctor or nurse 1311 303 23.1 19.0 13.7–24.4
Other 20579 2751 13.4 11.1 10.1–12.1
Urban/rural
Capital city (Municipalities) 13321 3052 22.9 17.1 15.7–18.4
Other urban areas 13791 3333 24.2 19.6 18.2–21.1
Rural areas 15188 3234 21.3 15.7 14.4–17.0
Region
Eastern 15483 3301 21.3 15.2 13.8–16.7
Central 15276 3554 23.3 18.6 17.3–19.8
Western 11541 2764 23.9 19.3 17.7–20.9
Total 42300 9619 22.7 17.1 16.1–18.0
NOTE. # 79 unvaccinated participants were missing occupation data.
doi:10.1371/journal.pone.0017919.t003
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reactivity with previous swine-origin influenza A viruses and is
consistent with data from Singapore, but not with recent data from
Taiwan [8,11]. The finding that individuals living in Eastern
regions had lower seroprevalence of pH1N1 infection compared
with individuals living in both Central and Western regions is
similar to findings from the Chinese National Surveillance System
during peak influenza periods, the hospital based surveillance
system that monitors trends of influenza-like illness. One possible
reason why the Eastern region experienced lower seroprevalence
of infection although this region is more densely populated and
includes most of the major cities in the country is that the eastern
region had higher economic level, higher education level and more
funding for health care than both the central and western regions
(expenditure for health care per capita in 2009: eastern, RMB
929.81; central, RMB 753.09; western, RMB 739.64) [25].
Additionally, our results showed that the seroprevalence of
pH1N1 infection was higher in urban areas compared to rural
areas. We speculate that the higher seroprevalence of pH1N1
infection in urban areas may be related to more frequent social
contacts and greater density of population. Our finding of
increased pH1N1 seroprevalence in school-aged children is
consistent with recent serological studies in other countries, as
well as a study conducted in Beijing, China [7,9,10,12,13]. In our
study, school-aged children had higher odds of antibody response
to pH1N1 infection compared with children in family care. The
observed higher odds of seropositivity may be the result of intense
social mixing patterns in schools and kindergartens possibly
contributing to transmission.
As of January 20, 2010, approximately 65.6 million people had
received pH1N1 vaccine in mainland China [26], which accounted
for 5% of the population. In contrast, our study found that 9.7% of
the population received the pH1N1 vaccine. One possible
explanation for the difference may be that individuals who reported
receiving the vaccine may have been more willing to participate in
the study or that participants misreported receiving any vaccine.
The observed antibody response among study subjects who
reported receiving the vaccine was lower (62%) than the antibody
positive rate from a clinical study in China. This study reported that
74.5–97.3% of the subjects receiving 15 mg of nonadjuvanted
vaccine achieved a HI titer $40 by day 21[23,24]. The percentage
of individuals reaching seropositivity in this study was also higher
than another study conducted in Beijing between late-November
and early-December, 2009, where 14.0% of participants reached
seropositivity [12]. Our findings showed the subjects reported
receiving vaccine still obtained higher seroprevalence than the
general population, who presumably experienced natural infection.
One possible reason for the lower seroprevalence among the
vaccinated population in our study population was that the interval
of time between vaccination date and sample collection which was
less than 2 weeks and may not have been enough time to develop
antibody response. Another possible reason could be recall bias with
self-reported vaccination history or misclassification of vaccine in
some individuals may report receiving pH1N1 vaccine, but may
have received a different vaccine.
The Chinese population had low pre-existing immunity to
pH1N1, but experienced a relatively high attack rate in 2009 of
this virus. Our finding of high seroprevalence of pandemic
influenza H1N1 (2009) (21.5%) after the first peak in autumn-
winter season of 2009–2010 in mainland China may explained
further by the theory that sustainable transmission is not likely
when a significant change in viral antigens is not acquired. Our
study findings help to enhance the understanding of the 2009
pH1N1 virus and provide valuable information for the Chinese
authorities to develop a vaccination strategy for the coming
influenza season.
Table 4. Adjusted odds ratios and 95% Confidence Intervals of pH1N1 infection among subjects who reported not receiving
pH1N1 vaccine (N=42,300).
Demographic Characteristics
Weighted prevalence of
pH1N1 antibody (%) Adjusted OR (95% CI) p-value
Gender
Male 18.2 1
Female 16.0 0.91 (0.79–1.04) 0.15
Occupation#
Children in family care 20.8 1
Children in kindergarten 26.2 1.36 (1.05–1.76) 0.0003
Student 34.9 2.04 (1.64–2.54) ,0.0001
Teacher 16.1 0.77 (0.41–1.44) 0.37
Doctor or nurse 19.0 0.82 (0.55–1.22) 0.30
Other 11.1 0.46 (0.37–0.58) ,0.0001
Urban/rural
Capital city (Municipalities) 17.1 0.97 (0.83–1.12) 0.19
Other urban areas 19.6 1
Rural areas 15.7 0.79 (0.69–0.90) 0.0003
Region
Eastern 15.2 0.80 (0.68–0.93) 0.0003
Central 18.6 1.02 (0.89–1.18) 0.02
Western 19.3 1
NOTE. # 79 unvaccinated participants were missing occupation data.
doi:10.1371/journal.pone.0017919.t004
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Baseline serological survey
To assess the baseline prevalence of cross-reactive antibody
response to 2009 pandemic H1N1, we used 2,379 stored serum
samples collected between 2006 and 2008. These samples were
collected from five provinces from different regions of mainland
China (Guangdong, Hubei, Shandong, Xinjiang, Yunnan, Figure
S2) and were divided into 5 age groups (0–5 years, 6–15 years, 16–
24 years, 25–59 years, $60 years). Sample sizes for the five age
groups ranged from 360 to 556 and more than half (51.1%) were
male.
Random-sampling cross-sectional seroprevalence study
Study design. In January 2010, a cross-sectional seropreve-
lance study to estimate the seroprevalence of 2009 pH1N1 virus
infection was approved by the Ministry of Health (MoH) as an
emergency study for pandemic response. To select subjects, we
utilized a multi-stage stratified random sampling method.
Sampling Method. There are 31 administrative divisions of
mainland China (22 provinces, 4 municipalities, 5 autonomous
regions) that were divided into eastern, central and western
regions by the National Bureau of Statistics of China. For this
study, 12 provinces were randomly selected to participate. Four
provinces (Beijing, Shandong, Shanghai and Guangdong) were
randomly selected from eastern region, four provinces (Henan,
Jilin, Anhui and Hunan) from central region, and four provinces
(Shaanxi, Xinjiang, Guizhou and Tibet) from western region
(Figure 1). Eleven of the twelve selected provinces agreed to
conduct the study; Tibet declined to participate. The catchment
population in the 11 provinces is 557.1 million, accounting for
approximately 43% of the total population in mainland China.
The remainder of the multi-stage random sampling method was
carried out by each province. Each province was divided into
three population strata, a) the core area of the capital city
(municipality), b) prefectures of other urban areas and c)
prefectures of rural areas. The provinces were then instructed
to randomly select at least two districts in each of the three
population strata, then 1–2 neighborhoods in each district and
finally 1–2 communities/villages in each neighborhood (Figure 2).
Once the communities were selected, sampling age groups for
subjects 0–5 years, 6–15 years, 16–24 years, 25–59 years and
$60 years were selected. Before the recruitment of participants,
the team responsible for the site survey obtained a name list of all
individuals (including age) residing in the communities/villages,
and randomly selected individuals from each of age group. With
the aid of community/village staff, the selected study subjects
were approached and asked if they would like to participate in the
study. Overall for each province, 300 persons from each age
group in each of the three population strata was the target to
enroll in the study. Selected subjects provided informed consent
and could decline participation. If a selected individual declined
to participate, the next individual on the list was contacted and
asked to participate. If the informed consent was obtained from
the study participant, the survey questionnaire was completed by
a trained interviewer and blood samples were collected. For
adults ($18 years), the informed consent was provided by
themselves. For adolescents (10–17 years), the assent was
provided by themselves and the informed consent was provided
by a parent or a legal guardian of the adolescent. For children
(,10 years), the informed consent was provided by a parent or a
legal guardian.
Sample Size. We expected the seroprevalence to be an
estimated 25% and for a 95% confidence interval of +/2 10%
(15–35%) we estimated the sample size of 300 from each age
group in each of the three strata in each province for an expected
sample size from each province of 4,500 and a total of 49,500
subjects.
Investigation and specimen collection
From January 6–29, 2010, a standard questionnaire was
administered by trained staff to subjects or guardians if the child
was #15 years of age. Information collected on the survey
included demographics (age, gender, occupation, etc.) and history
of a cold, defined as any upper respiratory illness, since May 1,
2009, and pH1N1 vaccination history. The question describing
occupation was asked of all individuals regardless of age and was
classified as children in family care, children in kindergarten,
student, teacher, doctor, and other. Children in family care are
defined as the persons aged #15 years that do not fit into other
categories such as children in kindergarten, students, or did not
work in any other organizations or units described in the question.
Blood samples were collected from each subject, 5 ml for subjects 6
years or older and 2–3 ml for children younger than 6 years.
Serum samples were separated at prefectural Centers for Disease
Control and Prevention (CDC) laboratories and then transported
to the provincial CDC. After the conclusion of the study, the
provincial CDC sent serum samples stored at -30uC and the
survey database to the Chinese National Influenza Center (CNIC)
of the National Institute for Viral Disease Control and Prevention
(IVDC) at China CDC in Beijing for laboratory testing and data
analysis.
Laboratory testing
The haemagglutination-inhibition (HI) assay using 0.5% turkey
red blood cells was used to test serum for antibody to pH1N1
according to standard protocols [27,28]. The 2009 pH1N1
antigen used was the A/California/07/2009 virus (provided by
U.S. CDC), which was propagated in specific pathogen-free (SPF)
embryonated chicken eggs and inactivated with 1% paraformal-
dehyde. A positive serum control (SPF Chicken anti-serum against
A/California/07/2009) and negative serum control (sera from
health populations before the outbreak of pandemic H1N1) were
included in each 96-well plate during the experiment. Prior to
testing by the HI assay, serum samples were treated with a 1:5
(vol/vol) of receptor destroying enzyme (RDE, prepared by CNIC)
at 37uC for 18 hours followed by incubation at 56uC for 30
minutes. Serum samples were titrated in 2-fold dilutions in
phosphate-buffered saline and tested at an initial dilution of 1:10.
Most individuals infected with influenza develop antibody titers
$40 by viral HI assay after recovery [7] and was therefore used as
marker for immunity against pH1N1 in this study.
Laboratory Quality Control
National specialist groups were convened to guide statistical
design, epidemiological investigation, laboratory testing, training
and data analysis. Site supervisions by CDC at national or
provincial level were conducted during the site investigation. All
the villages were selected at the provincial level. Trained County
CDC staffs were responsible for administering the questionnaire,
collecting the blood specimens, and separating, storing and
transporting the serum specimens. Bar code, material for sera
collection and separation were provided by CNIC. Five-percent of
serum samples were randomly selected from all samples were
tested to assess the within-laboratory reproducibility. No more
than 18% of replicate tests differed by more than 2-fold. The
average reproducibility for positive and negative value is 92%.
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CNIC issued a standard database to all study sites, which was
created in EPI Data software (version 3.02). The survey
questionnaires were double inputted into the database and
checked for consistency within the provinces. Data were analyzed
at CNIC, with SAS 9.1 (SAS Institute, Cary, NC, U.S.) software.
Applying weights to the data
Appropriate sampling weights were constructed for the national
database and applied to seroprevalence data to account for the
complex sampling design [29–31] and to adjust for age and
community setting (capital, urban, rural) which were not represen-
tatively sampled. The weight components computed for these data
were based on previously published weighting methodology which
consisted of base weights and adjustment weights [29–31]. A base
weight denotes the probability of selecting a participant from the
total number of the sampling units of each sampling stage. Then
adjustment weights were calculated to adjust seroprevalence of
pH1N1 for differences between census characteristics of study
sample and characteristics of the chinese population. The base
weight of each sampling stage was calculated by dividing the total
number of the sampling unit (e.g. province, capital city, district,
neighborhood, village/community, and individual r) by the number
of each sampling unit selected, described in Table S1. For example,
the base weight for Guangdong Province on the first sampling stage
was calculated by dividing the total number of eastern provinces (9)
by the number of eastern provinces selected (4). The total base
weightforaperson(i)was then calculated bymultiplying each ofthe
base weights for each selected sampling unit including the person i
on each sampling stage. Next the adjusted weights were calculated
accounting for gender (male, female), age group (0–5 years, 6–15
years, 16–24 years, 25–59 years, and $60 years) and community
type (capital city, urban area, or rural area). The adjusted weight of
person i was calculated based on the combination of the three strata
(age group, gender, and community type) that person i fit into by
dividing the actual Chinese population for the combination by the
sum of the base weights of all sampled individuals for the same
combination of the strata that person i fell into, described in Table
S2. The sampling weight of each selected individual was calculated
by multiplying the total base weight by the adjustment weight.
Figure 1. 11 provinces selected randomly from eastern, central and western regions in the serological cross-sectional survey in
January 2010. Western provinces include: Chongqing, Gansu, Guangxi, Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, Sichuan, Tibet, Yunnan,
and Xinjiang. Central provinces include: Anhui, Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi. Eastern provinces include:
Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang.
doi:10.1371/journal.pone.0017919.g001
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serological response to pH1N1 infection, we conducted multivar-
iable logistic regression analyses. The dependent variable was
presence of pH1N1 seropositivity vs. no seropositivity. Indepen-
dent variables examined were gender, occupation, location of
communities (capital city or rural areas vs. other urban areas),
region (eastern or central vs. western). The final model examining
risk factors for pH1N1 infection included gender, occupation,
region, and location of communities (capital city or rural vs. other
urban areas). Age group was excluded from the model because of
the collinear relationship with occupation (p,0.0001). The
surveyfreq procedure in the SAS software package was used to
calculate the point estimates and 95% confidence intervals of
weighted prevalence and the surveylogistic procedure was used for
multivariable logistic regression to examine odds of infection for
risk factors [32].
Supporting Information
Figure S1 Number of laboratory-confirmed pH1N1
cases and time when the serological cross-sectional
survey conducted.
(TIF)
Figure S2 Geographical distribution of stored serum
samples collected between 2006 and 2008.
(TIF)
Table S1 The calculation of base weights in each of 6
random sampling stage. The base weight for person i can be
expressed as follows: Wbasei= W1 6W26W36W46W56W6
(DOC)
Table S2 The calculation of adjustment weights. Adjust-
ment weights (Wadj) were constructed based on post-stratification
adjustmentstoaccountfortheregion,sexand agedistributionofthe
entire Chinese population. If person i is located in the cell (row r,
column c), his/her adjustment weight can be expressed as follows:
wadji~
Nrc Pnrc
i~1 wbasei
Nrc refers to the actual size of the Chinese population in the cell
(row r, column c);n rc refers to the sample size in the cell (row r, column
c);
Pnrc
i~1 wbasei refers to the sum of base weights of all study
individuals in the cell (row r, column c).
(DOC)
Figure 2. The sampling procedures in the serological cross-sectional survey in January 2010.
doi:10.1371/journal.pone.0017919.g002
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